The Torlak Institute has signed a Technology Transfer Agreement with the Russian Direct Investment Fund and the Russian pharmaceutical company Generium, which makes this possible.
Popovic pointed out that from this moment, data related to the production of the "Sputnik V" vaccine, which was developed by the most renowned Russian institute for virology "Gamaleya", have been opened for Torlak.
It is about sensitive and confidential data that can be exchanged only by partners who have huge mutual trust, the Minister assessed and announced that three validation series of the "Sputnik V" vaccine will be produced at the Torlak Institute in April.
According to him, samples from these validation series will be sent for quality control to the Gamaleya Institute in Moscow, and after that institute will confirm the validity of the samples produced in Torlak, upon which the Torlak Institute will start producing the vaccine.
We expect that to happen by 20 May this year, Popovic said and pointed out that in that way, Serbia would become the first country in Europe to produce the "Sputnik V" vaccine.